Discovery of novel Thymol-TPP antibiotics that eradicate MRSA persisters

Area of Science:

• Microbiology
• Drug Discovery
• Biochemistry

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant health threat due to antibiotic resistance.
• Bacterial persisters, dormant cells, evade antibiotic treatments, complicating therapy.
• Novel strategies are urgently needed to combat MRSA infections and resistance.

Purpose of the Study:

• To design and synthesize novel Thymol triphenylphosphine (TPP) conjugates.
• To evaluate the efficacy of these conjugates against MRSA, particularly persister cells.
• To investigate the mechanism of action of the most effective conjugate.

Main Methods:

• Synthesis of TPP-Thymol conjugates (TPP-Thy3).
• Antimicrobial activity testing against Gram-positive bacteria and MRSA persisters.
• Mechanism of action studies using fluorescence, electron microscopy, molecular dynamics, and bilayer experiments.
• In vivo efficacy testing in a mouse infection model.

Main Results:

• TPP-Thy3 conjugates showed enhanced antibacterial activity compared to Thymol.
• Thy3d demonstrated potent killing of MRSA persisters (99.999%) with low resistance selection probability and good biocompatibility.
• Mechanism studies confirmed membrane disruption as the mode of action.
• Thy3d showed efficacy in a murine MRSA infection model.

Conclusions:

• TPP-Thy3 conjugates represent a novel class of antibacterial agents.
• Thy3d is a promising candidate for combating MRSA infections, including persister cells.
• These conjugates offer a potential new therapeutic strategy against antibiotic resistance.